United Therapeutics Corporation
General ticker "UTHR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $15.6B (TTM average)
United Therapeutics Corporation follows the US Stock Market performance with the rate: 46.9%.
Estimated limits based on current volatility of 1.2%: low 465.66$, high 476.62$
Factors to consider:
- Total employees count: 1305 (+11.7%) as of 2024
- US accounted for 35.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on treprostinil based therapies, Market competition, Product recalls, Supply chain disruptions, Third-party risks
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [302.67$, 430.67$]
- 2025-12-31 to 2026-12-31 estimated range: [312.68$, 448.32$]
Financial Metrics affecting the UTHR estimates:
- Negative: with PPE of 14.6 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 47.86 > 18.33
- Positive: 6.63 < Operating cash flow per share per price, % of 8.16
- Positive: Return on assets ratio (scaled to [-100,100]) of 13.96 > 6.04
- Positive: Interest expense per share per price, % of 0.26 <= 0.74
- Positive: Shareholder equity ratio, % of 87.51 > 64.17
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0.62 <= 0.82
Short-term UTHR quotes
Long-term UTHR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,936.30MM | $2,327.50MM | $2,877.40MM |
| Operating Expenses | $956.60MM | $1,142.60MM | $1,500.40MM |
| Operating Income | $979.70MM | $1,184.90MM | $1,377.00MM |
| Non-Operating Income | $-29.10MM | $89.40MM | $162.00MM |
| Interest Expense | $32.40MM | $59.30MM | $42.90MM |
| R&D Expense | $322.90MM | $408.00MM | $481.00MM |
| Income(Loss) | $950.60MM | $1,274.30MM | $1,539.00MM |
| Taxes | $223.30MM | $289.50MM | $343.90MM |
| Profit(Loss)* | $727.30MM | $984.80MM | $1,195.10MM |
| Stockholders Equity | $4,796.70MM | $5,984.80MM | $6,444.00MM |
| Inventory | $102.00MM | $111.80MM | $157.90MM |
| Assets | $6,044.50MM | $7,167.00MM | $7,364.00MM |
| Operating Cash Flow | $802.50MM | $978.00MM | $1,327.10MM |
| Capital expenditure | $138.80MM | $230.40MM | $246.50MM |
| Investing Cash Flow | $-811.50MM | $-719.60MM | $417.20MM |
| Financing Cash Flow | $75.40MM | $-11.90MM | $-1,254.80MM |
| Earnings Per Share** | $15.98 | $21.04 | $26.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.